Form 4 for AARD Aardvark Therapeutics, Inc.
Accepted 2025-10-16 00:00:00 ET · period of report 2025-10-15 · accession 0001193125-25-241647 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-16 | 2025-10-15 | AARD | Lee Tien-Li | CEO, Dir, 10% | M - OptEx | $4.24 | +1,229 | 1.54M | +0.1% | +$5,211 |
| D | 2025-10-16 | 2025-10-15 | AARD | Lee Tien-Li | CEO, Dir, 10% | M - OptEx | $0.00 | -1,229 | 40.6K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-15 | M | A | 1,229 | $4.24 | 1,544,613 | D | — | — | |
| 2 | Derivative | Stock option (right to buy) | 2025-10-15 | M | D | 1,229 | $0.00 | 40,566 | D | $4.24 · — to 2034-07-20 | 1,229 Common Stock | (F1) 1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. |